Innovations in Osteoarthritis (OA) Treatment

 

Please join us online for our free Health Professional Webinars as part of Musculoskeletal Health Awareness Month!

Innovations in Osteoarthritis (OA) Treatment

 

Osteoarthritis (OA) is not only a major cause of disability and health care costs, it is also associated with increased death from cardiovascular disease. Innovations in OA treatment need to consider, not only new treatments, but also new and modified approaches to prevention, early management and targeting of major co-morbidities. OA is not a single disease and the drivers of disease vary across different joint groups. This is important in order to develop effective treatments.

Inflammation has an important role in pain and joint damage in hand OA. Recent data has shown that methotrexate results in a moderate and significant improvement in pain and function in hand OA with inflammation. Obesity, a major risk factor for knee OA, effects knees though both loading and metabolically driven inflammation over the course of many years, highlighting the importance of both preventing weight gain as well as weight loss. Weight loss is difficult to achieve.

There is a lot of interest in the glucagon-like peptide-1 agonists such as semaglutide. The evidence for these medication in OA will be reviewed. Exercise is important for maintaining healthy joints. However recent evidence questions the role of specific therapeutic exercise programs. What does this mean for patients? There is a lot of interest in treatments such as stem cell therapies and platelet rich plasma. Should they be used? Over the last decade, there has been a trend for knee replacements to be performed for earlier OA. Have we got this right? These are issues that will be considered in this presentation.

 

Presenter: Flavia is Professor and Head of Rheumatology at the Alfred Hospital, the Musculoskeletal Unit at Monash University and an NHMRC Leadership Fellow. Flavia’s principle research interests are the prevention and treatment of musculoskeletal diseases, with over 660 publications. Her work using novel methods for assessing joint health has underpinned changes in the understanding of the mechanism of disease in osteoarthritis, has identified new treatment approaches and has underpinned novel clinical trials that have resulted in new treatments for OA.

Flavia is currently serving on the council of the Australian Academy of Health & Medical Sciences, the AIHW National Arthritis and Musculoskeletal Monitoring Advisory Group, the Repatriation Medical Authority, on the editorial board of a number of journals and recently on the Board of the Osteoarthritis Research Society International. She has been the recipient of numerous awards.
Her current work is focussed on improving outcomes for patients with musculoskeletal disease by developing new treatments and models of care focussed on the delivery of effective, feasible, evidence–based care.

 

 

Have you checked out our other webinars?

We have a huge list of interesting webinars from with links to the FREE recordings! We try and cover a range of topics from specific conditions to ways to manage day–to–day. Check them out here.

 

Date

Wednesday Oct 9th 2024

Time

12:30 pm - 1:30 pm

Local Time

  • Timezone: America/New_York
  • Date: Tuesday Oct 8th 2024
  • Time: 9:30 pm - 10:30 pm

More Info

Book Now

Location

Online
Category

Organizer

Musculoskeletal Health Australia
Phone
03 8531 8000
Email
info@muscha.org
Book Now

Speaker

QR Code
musculoskeletal health australia

Musculoskeletal Health Australia (or MHA) is the consumer organisation working with, and advocating on behalf of, people with arthritis, osteoporosis, back pain, gout and over 150 other musculoskeletal conditions.

Useful Links


Recent Posts

Copyright by Musculoskeletal Health Australia 2024. All rights reserved

ABN: 26 811 336 442ACN: 607 996 921